Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06195384
PHASE1

Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors

Sponsor: Second Affiliated Hospital of Guangzhou Medical University

View on ClinicalTrials.gov

Summary

The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.

Official title: Anti-cancer Neoantigen mRNA Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-05-08

Completion Date

2037-12-30

Last Updated

2024-06-26

Healthy Volunteers

No

Interventions

BIOLOGICAL

Neoantigen mRNA Vaccine

Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.

Locations (1)

Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China